(S)-Desmethylzopiclone | 151776-26-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡嗪类
• 英文名称: (S)-Desmethylzopiclone
• 英文别名: [(7S)-6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] piperazine-1-carboxylate
• CAS: 151776-26-0
• 化学式: C₁₆H₁₅ClN₆O₃
• 分子量: 374.78
• InChiKey: CGSFZSTXVVJLIX-HNNXBMFYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  右佐匹克隆 以27的产率得到(S)-Desmethylzopiclone
  参考文献：
  名称：

  Methods of making and using N-desmethylzopiclone

  摘要：

  本发明涉及包含及使用外消旋N-去甲基唑吡克隆、光学纯(+)-N-去甲基唑吡克隆和光学纯(−)-N-去甲基唑吡克隆的组合物在哺乳动物的疾病和状况的治疗和预防方面的方法。本发明还涉及制备N-去甲基唑吡克隆、光学纯(+)-N-去甲基唑吡克隆和光学纯(−)-N-去甲基唑吡克隆的新方法。

  公开号：

  US06339086B1

文献信息

• DRUG FRAGMENT IMAGING AGENT CONJUGATES
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US20200390909A1

  公开（公告）日：2020-12-17

  Functional dyes and methods of use are provided. The dyes are useful in a variety of medical applications including, but not limited to, diagnostic imaging and therapy, endoscopic applications for the detection of tumors and other abnormalities, particularly with oral administration of the dyes.

  本发明提供功能染料及其使用方法。这些染料可用于各种医学应用，包括但不限于诊断成像和治疗，内窥镜应用以检测肿瘤和其他异常情况，特别是通过口服染料。
• Methods of making and using N-desmethylzopiclone
  申请人：Swpracor, Inc.

  公开号：US06339086B1

  公开（公告）日：2002-01-15

  The invention is directed to compositions comprising, and methods of using, racemic N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (−)-N-desmethylzopiclone in the treatment and prevention of diseases and conditions in mammals. The invention is further directed to novel methods of preparing N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (−)-N-desmethylzopiclone.

  本发明涉及包含及使用外消旋N-去甲基唑吡克隆、光学纯(+)-N-去甲基唑吡克隆和光学纯(−)-N-去甲基唑吡克隆的组合物在哺乳动物的疾病和状况的治疗和预防方面的方法。本发明还涉及制备N-去甲基唑吡克隆、光学纯(+)-N-去甲基唑吡克隆和光学纯(−)-N-去甲基唑吡克隆的新方法。
• Compositions comprising zopiclone derivatives and methods of making and using the same
  申请人：Jerussi P. Thomas

  公开号：US20070049590A1

  公开（公告）日：2007-03-01

  The invention is directed to racemic and stereomerically pure compounds of Formula 3: and to pharmaceutical compositions comprising them, methods of their use, and methods of their preparation.

  该发明涉及公式3的外消旋和立体异构纯化化合物，以及包含它们的制药组合物、使用方法和制备方法。
• [EN] PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF<br/>[FR] DÉRIVÉ DE PHOSPHAMIDE, SON PROCÉDÉ DE FABRICATION ET SES UTILISATIONS<br/>[ZH] 一种磷酰胺衍生物及制备方法和用途
  申请人：SICHUAN HAISCO PHARMACEUTICAL CO LTD

  公开号：WO2017133517A1

  公开（公告）日：2017-08-10

  公开了一种磷酰胺衍生物及制备方法和用途。特别公开了一种通式(I)所示化合物及其药学上可接受的盐或立体异构体 (I)，其中，G、L、Q、s如说明书中所定义。
• Dopamine-Agonist Combination Therapy For Improving Sleep Quality
  申请人：Barberich Timothy J.

  公开号：US20100004251A1

  公开（公告）日：2010-01-07

  The present invention generally relates to pharmaceutical compositions comprising a dopamine agonist and sedative agent. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine. In a preferred embodiment, the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine; and the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone. The pharmaceutical compositions of the invention are useful in the treatment of restless-leg syndrome and periodic-limb-movement disorder, as well as various sleep disorders. In addition, the present invention relates to a method of treating a patient suffering from restless-leg syndrome, periodic-limb-movement disorder, a sleep abnormality, or insomnia, comprising coadministering a therapeutically effective amount of a dopamine agonist and a therapeutically effective amount of a sedative agent. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine. In a preferred embodiment, the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine; and the sedative agent is optically pure (S)-zopiclone or optically pure (S)—N-desmethylzopiclone.